Crigler-Najjar Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Crigler-Najjar syndrome is a severe condition characterized by high levels of a toxic substance called bilirubin in the blood. Symptoms include yellow skin and yellow in the whites of the eyes. It occurs when the enzyme that normally converts bilirubin into a form that can easily be removed from the body does not work correctly. Treatment includes phototherapy, liver transplantation, and blood transfusions.
The Crigler-Najjar Syndrome Drugs in Development market research report provides an overview of the Crigler-Najjar Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Crigler-Najjar Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crigler-Najjar Syndrome and features dormant and discontinued projects.
Crigler-Najjar Syndrome Pipeline Drugs Market Targets
The target of the Crigler-Najjar Syndrome pipeline drugs market is UDP Glucuronosyltransferase 1-1.
Mechanisms of Action of Crigler-Najjar Syndrome Pipeline Drugs Market
The mechanism of action of the Crigler-Najjar Syndrome pipeline drugs market is UDP Glucuronosyltransferase 1-1 Activator.
Routes of Administration in Crigler-Najjar Syndrome Pipeline Drugs Market
The routes of administration in the Crigler-Najjar Syndrome pipeline drugs market are intravenous and parenteral.
Crigler-Najjar Syndrome pipeline drugs market, by routes of administration
For more routes of administration insights, download a free report sample
Key Crigler-Najjar Syndrome Pipeline Drugs Market Companies
Some of the key companies in the Crigler-Najjar Syndrome pipeline drugs market are International Stem Cell Corp, Logicbio Therapeutics Inc, Moderna Inc, Selecta Bioscience Inc, and Promethera Biosciences SA.
Crigler-Najjar Syndrome pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report overview
Target | UDP Glucuronosyltransferase 1-1 |
Mechanism of Action | UDP Glucuronosyltransferase 1-1 Activator |
Routes of Administration | Intravenous and Parenteral |
Molecule Types | Cell Therapy, Gene Therapy, and Oligonucleotide |
Key Companies | International Stem Cell Corp, Logicbio Therapeutics Inc, Moderna Inc, Selecta Bioscience Inc, and Promethera Biosciences SA |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Crigler-Najjar Syndrome (Genetic Disorders).
- Reviews of pipeline therapeutics for Crigler-Najjar Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key companies involved in Crigler-Najjar Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- Evaluation of Crigler-Najjar Syndrome (Genetic Disorders) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Crigler-Najjar Syndrome (Genetic Disorders).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Crigler-Najjar Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Crigler-Najjar Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Crigler-Najjar Syndrome pipeline drugs market?
The target of the Crigler-Najjar Syndrome pipeline drugs market is UDP Glucuronosyltransferase 1-1.
-
What are the mechanisms of action of the Crigler-Najjar Syndrome pipeline drugs market?
The mechanism of action of the Crigler-Najjar Syndrome pipeline drugs market is UDP Glucuronosyltransferase 1-1 Activator.
-
What are the routes of administration in the Crigler-Najjar Syndrome pipeline drugs market?
The routes of administration in the Crigler-Najjar Syndrome pipeline drugs market are intravenous and parenteral.
-
What are the molecule types in the Crigler-Najjar Syndrome pipeline drugs market?
The molecule types in the Crigler-Najjar Syndrome pipeline drugs market are cell therapy, gene therapy, and oligonucleotide.
-
Which are the key companies in the Crigler-Najjar Syndrome pipeline drugs market?
Some of the key companies in the Crigler-Najjar Syndrome pipeline drugs market are International Stem Cell Corp, Logicbio Therapeutics Inc, Moderna Inc, Selecta Bioscience Inc, and Promethera Biosciences SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.